世界卫生组织已将首个Bundibugyo病毒(BDBV)分子诊断测试添加至紧急使用清单1。该测试通过识别血液样本中的病毒遗传物质，能够快速准确地确认感染1。
截至报道时间，刚果民主共和国已报告1406例实验室确诊病例和438例死亡1。WHO正在与制造商和全球伙伴合作，扩大诊断工具的可获得性1。实验室检测能力已从原来的每天200-400次扩展至10个实验室网络每天2000次以上1。
WHO卫生应急助理总干事Yukiko Nakatani表示："在快速变化的疫情中，及时获得质量有保证的诊断测试在遏制传播方面可能产生关键影响"1。
WHO正与Africa CDC、PATH、FIND、CHAI等伙伴建立联合验证平台，以评估多种诊断产品的性能1。
The World Health Organization has added the first molecular diagnostic test for Bundibugyo virus (BDBV) to its Emergency Use Listing, enabling rapid and accurate identification of the virus through detection of genetic material in blood samples.1 This approval comes as the outbreak continues in the Democratic Republic of the Congo, where authorities have confirmed 1,406 laboratory-verified cases and 438 deaths to date.1
The expansion of diagnostic capacity represents a significant advancement in outbreak response. Laboratory testing capabilities have scaled from an initial 200–400 tests per day to over 2,000 tests daily across a network of 10 laboratories.1 According to Dr. Yukiko Nakatani, "timely access to quality-assured diagnostic tests can be critical in containing transmission amid rapidly evolving outbreak conditions."1 The WHO is collaborating with manufacturers and global partners, including the Africa CDC, PATH, FIND, and CHAI, to establish a joint validation platform for assessing the performance of multiple diagnostic products and broadening the availability of testing tools.1
评论
还没有评论，欢迎留下第一条。